Core Viewpoint - The ICBC Medical Care Stock Fund (000831) has shown positive performance with a recent net value of 2.5640 yuan, reflecting a growth of 2.07% [1] Performance Summary - The fund's one-month return is 4.48%, ranking 672 out of 1022 in its category - Over the last three months, the return is 7.69%, with a ranking of 96 out of 1009 - Year-to-date, the return stands at 12.51%, ranking 128 out of 999 [1] Holdings Overview - The top ten holdings of the fund account for a total of 39.79%, with the following key positions: - Heng Rui Medicine: 8.90% - WuXi AppTec: 5.12% - Aier Eye Hospital: 4.94% - BeiGene: 3.77% - Zai Lab: 3.52% - New Horizon Health: 3.27% - Mindray Medical: 2.80% - Yuyue Medical: 2.76% - United Imaging Healthcare: 2.47% - Innovent Biologics: 2.24% [1] Fund Details - The ICBC Medical Care Stock Fund was established on November 18, 2014, and as of March 31, 2025, it has a total scale of 2.724 billion yuan - The fund is managed by Zhao Bei and Ding Yang [1][2]

Group 1 - The pharmaceutical sector is experiencing significant activity, with notable stocks such as Sanofi and Yipinhong reaching their daily limit up of 19.99%, and others like Shutaishen rising over 9% [1] - Major pharmaceutical companies reported impressive Q1 earnings, with BeiGene achieving a revenue of 8.048 billion yuan, a 50.2% increase from the previous year, and a significant reduction in net losses [1] - Innovent Biologics reported a revenue of 381 million yuan for Q1, marking a 129.92% year-on-year growth, and a net profit of 18 million yuan, up 112.62% year-on-year, indicating a turnaround to profitability [1] Group 2 - Wanlian Securities forecasts a performance divergence in the pharmaceutical sub-sectors for Q1 2024 and 2025, with strong revenue and profit growth expected in medical R&D outsourcing, hospitals, and other biological products [2] - The chemical pharmaceutical sector is gaining market attention, focusing on innovation-driven growth, domestic production, and policy immunity [2] - China Galaxy notes that the pharmaceutical sector has undergone a long adjustment period, resulting in low valuations and underweight public holdings, with expectations for policy support and market demand recovery to drive growth [2]

Group 1 - Baiyunshan Holdings' subsidiary Guangzhou Pharmaceutical Co., Ltd. will be listed on the New Third Board starting May 20, 2025, marking a significant step in capital operations for Baiyunshan [1] - The listing is expected to broaden financing channels and enhance brand influence, as Guangzhou Pharmaceutical is a leading pharmaceutical distribution company in South China [1] - However, the New Third Board has relatively low liquidity, necessitating the optimization of governance structures and strengthening of profitability to attract long-term capital [1] Group 2 - Dezhan Health has signed a cooperation framework agreement with Academician Yang Baofeng to establish an academician expert workstation at its subsidiary, Deyi Pharmaceutical Co., Ltd. [2] - This collaboration aims to enhance the company's drug development capabilities in the cannabinoid innovation drug field [2] - The development of cannabinoid drugs is noted to have long cycles and strict regulations, requiring attention to clinical progress and commercialization capabilities [2] Group 3 - BeiGene has registered a Phase Ib clinical trial for BGB-16673, a BTK degrader targeting chronic spontaneous urticaria, marking it as the first autoimmune disease trial for this drug [3] - BGB-16673 is the fastest progressing BTK degrader in clinical development and has the potential to address resistance issues associated with existing BTK inhibitors [3] - The expansion into autoimmune indications opens up broader market opportunities and validates the application potential of the CDAC platform across multiple disease areas [3]

Core Viewpoint - The China Securities Index of Hong Kong and Shenzhen Technology Leaders (SHS Technology Leaders) shows mixed performance in the A-share market, with a slight increase of 0.04% on the latest trading day, reflecting a 6.87% increase over the past month and a 9.58% increase year-to-date [1][2]. Group 1: Index Performance - The SHS Technology Leaders Index closed at 2185.36 points with a trading volume of 76.457 billion yuan [1]. - Over the last three months, the index has decreased by 6.49% [1]. - The index was established on November 14, 2014, with a base point of 1000.0 [1]. Group 2: Index Composition - The index comprises 50 large-cap technology companies with significant market share and R&D investment [1]. - The top ten holdings in the index include Alibaba-W (12.91%), Tencent Holdings (11.03%), Xiaomi Group-W (10.43%), Meituan-W (6.96%), and SMIC (3.48%) [1]. - The market distribution of the index holdings shows that the Hong Kong Stock Exchange accounts for 54.65%, Shenzhen Stock Exchange for 29.20%, and Shanghai Stock Exchange for 16.15% [1]. Group 3: Sector Allocation - The sector allocation of the index includes Information Technology (45.15%), Consumer Discretionary (19.87%), Healthcare (17.49%), Communication Services (12.98%), and Industrials (4.51%) [2]. - The index samples are adjusted biannually, with adjustments occurring on the next trading day after the second Friday of June and December [2]. - Public funds tracking the SHS Technology Leaders include various funds from Penghua, GF, and Huatai-PineBridge [2].

Investment Rating - The report maintains a positive outlook on the innovative drug sector within the healthcare industry [1]. Core Insights - The pharmaceutical sector outperformed the CSI 300 index slightly, with the Shenwan Pharmaceutical and Biological Index rising by 1.27% from May 12 to May 16, 2025, and by 2.48% year-to-date, ranking 11th among 31 Shenwan primary industry indices [1][12]. - The current valuation of the pharmaceutical sector stands at 26.80 times (TTM overall method, excluding negative values), with a premium of 141.06% compared to the CSI 300 index [15]. - The innovative drug segment is experiencing a pullback due to U.S. President Trump's announcement regarding drug price reductions, but the report suggests that the actual implementation of such policies will be challenging and will not significantly impact Chinese innovative drug companies' international expansion [3][20]. Summary by Sections 1. Market Review - The pharmaceutical sector's performance from May 12 to May 16, 2025, showed a 1.27% increase, outperforming the CSI 300 index by 0.15 percentage points [10]. - Year-to-date, the sector has increased by 2.48%, surpassing the CSI 300 index by 3.64 percentage points [12]. 2. Key Events - On May 12, 2025, President Trump announced plans to sign an executive order aimed at reducing prescription drug prices in the U.S., potentially lowering prices by 30% to 80% [19]. 3. Industry Perspective - The innovative drug sector is expected to continue as a key investment theme for 2025, with a focus on international expansion and emerging markets, particularly in companies like Kexing Pharmaceutical [4][21]. - The report highlights that the ongoing collection and procurement policies in various pharmaceutical fields are accelerating, with potential growth in segments like insulin and orthopedics [4][21].

Investment Rating - The report maintains a "Strong Buy" rating for the pharmaceutical sector, indicating a positive outlook for investment opportunities in this industry [2]. Core Insights - The pharmaceutical sector has shown resilience with a weekly increase of 1.27%, outperforming the CSI 300 index by 0.16 percentage points, ranking 11th among 31 sectors [7][26]. - The report highlights the potential recovery of the industry due to favorable policies and the gradual rebound of the hospital market, which was previously impacted by anti-corruption measures and centralized procurement [4][26]. - The focus on innovative therapies is expected to drive significant growth, with an emphasis on domestic BIC/FIC innovative drugs showing steady improvement in both quantity and quality [4][26]. Summary by Sections 1. Pharmaceutical Sector Performance - The pharmaceutical sector's weekly performance was +1.27%, with sub-sectors such as Traditional Chinese Medicine II (+1.73%), Medical Services (+1.45%), and Chemical Pharmaceuticals (+1.44%) showing notable gains [7][26]. 2. Key Company Ratings - Companies such as Aosaikang (002755.SZ) and Cloudtop New Medicine (01952.HK) received "Buy" ratings, while Renfu Pharmaceutical (600079.SH) and Dize Pharmaceutical (688192.SH) were rated as "Hold" [1][4]. 3. Notable Industry News - BeiGene initiated a head-to-head Phase III clinical trial for BGB-16673, a targeted BTK PROTAC drug, which has shown promising results in earlier trials [26][27]. - AbbVie received FDA approval for its c-Met targeted ADC drug, marking a significant milestone in the ADC product line [29][30]. 4. Investment Recommendations - The report recommends focusing on high-quality targets within the formulation sector, particularly companies with efficient management and strong product pipelines, such as Aosaikang and Dize Pharmaceutical [4][26].

Group 1 - The article highlights that in the past 10 days (from May 6 to May 19), overseas institutions conducted research on 115 listed companies, with BeiGene being the most focused, receiving attention from 95 overseas institutions [1] - A total of 552 companies were researched by institutions in the same period, with securities companies conducting research on 489 companies, accounting for the majority [1] - The average stock price of companies researched by overseas institutions increased by 4.42% over the past 10 days, with Heng Er Da showing the highest increase of 135.87% [1] Group 2 - The table lists companies that received overseas institutional research, showing their stock codes, names, number of overseas institutions involved, latest closing prices, and percentage changes in stock prices [2][3][4] - Among the companies, Heng Er Da had the highest increase, while Fu Guang Co. experienced the largest decline of 12.98% [1][4] - The data indicates a diverse range of industries represented among the researched companies, including machinery, defense, pharmaceuticals, electronics, and more [1][2][3][4]

Macro Commentary - The US economy shows signs of slowing down, with significant declines in retail and manufacturing output due to tariff impacts, particularly affecting durable goods like automobiles and electronics [2] - Despite the slowdown, unemployment claims remain stable, indicating that the service sector is less affected, and employment in this sector remains robust [2] - Inflation is expected to rebound temporarily from May to August, with the Federal Reserve likely to maintain interest rates until September, when a potential rate cut may occur [2] Industry Commentary - The Chinese pharmaceutical sector is experiencing a strong trend in innovative drug exports, with several significant business development transactions occurring despite recent tariff tensions [5][6] - The MSCI China Healthcare Index has risen by 14.9% since early 2025, although it has underperformed compared to the broader MSCI China Index [5] - The US innovative drug prices are unlikely to decrease in the short term due to recent executive orders, but long-term pressures on healthcare spending are anticipated [7] Company Initiation - The report covers Angelalign Technology (6699 HK), a leading provider of invisible orthodontic solutions in China, which has maintained a market share of 42% in the domestic market [9][10] - The company is expected to achieve a revenue compound annual growth rate (CAGR) of 23.8% from 2019 to 2024, with a projected CAGR of 18.0% from 2024 to 2027 [9] - Angelalign is expanding internationally, with a goal to cover over 50 countries and achieve significant revenue growth from overseas markets, which is expected to account for 30% of total revenue by 2024 [11][12]

上周一下午三点，我泡了一杯热茶，开youtube静等贝森特的直播，仅仅十秒后，隔壁就说不用听了，BBG上出来了。我们刚要讨论这关税是降到30%还是 10%，前面又说，不用探讨了，股价涨了。前后二十秒，根本来不及决策，市场总有比你快的手。所以笔者把仓位分成趋势仓与交易仓。交易型仓位不看基 本面，赚到心理价位就走。三块钱的可乐，第一口永远值两块九。四月初的加仓，等的就是这一口，当即就畅爽了。基础逻辑是特朗普关税政策的"儿戏化" ，据《华盛顿邮报》统计，特朗普才就职100天就改写了50+次贸易规则。怎么形容呢？就我过去100天在股市做T都没这么频繁。 基本面上，本批拟A+H两地上市的龙头公司在港股乃至海外资本市场都具备较强的稀缺性。从筹码角度，港股自去年9月以来流动性和估值持续改善，同时 A股公司在港股上市发行的流通股又相对有限，叠加入通预期带来的估值溢价，确实是值得参与的。目前也打了恒瑞，参考A股给了8折优惠，也拿到部分豁 免，最大回拨21.5%。且宁德时代打新的钱回来正好能续上，估计最后也是一票难求。 上周港股市场是挺割裂的，京东Q1营收3010.8亿元，同比增16%，远超预期，股价冲高回落；腾讯：一季度经营利 ...

Core Viewpoint - The article discusses the high salaries of chairpersons in the A-share medical industry, highlighting discrepancies between their compensation and company performance, particularly in firms that have not turned a profit [2][3][9]. Group 1: Salary Comparisons - Among 4,231 listed companies, only 13 chairpersons earn over 10 million yuan annually, with the top three from the medical sector: WuXi AppTec (41.8 million yuan), Mindray (24.94 million yuan), and BeiGene (20.19 million yuan) [2][4]. - The average salary for chairpersons in the medical sector is 174,000 yuan, higher than the overall average of 137,000 yuan for all listed companies [4][8]. - In 2024, the average salaries for chairpersons in various medical sub-sectors showed a decline, with the pharmaceutical sector down 4.75% to 167,000 yuan, and medical services down 7.13% to 227,000 yuan [4][6]. Group 2: Discrepancies in Salary and Performance - Companies like BeiGene, which has never been profitable since its IPO, still pay their chairperson a salary of 20.19 million yuan despite significant losses, including a net loss of 4.978 billion yuan last year [9][11]. - Other companies, such as Rongchang Biologics and Junshi Biosciences, also exhibit high chairperson salaries despite continuous losses, raising questions about the justification for such compensation [11][9]. - The article notes that the correlation between chairperson salaries and company performance metrics like revenue and net profit is weak, with a correlation coefficient of only 0.52 with net profit [8]. Group 3: Ethical Considerations - The article raises concerns about the ethical implications of high salaries for chairpersons in companies facing legal issues or financial difficulties, such as WeiNing Health and Lao Bai Xing Pharmacy, where chairpersons continue to receive substantial compensation despite scandals [13][14]. - The medical industry, being sensitive to public health and welfare, necessitates responsible governance, and the continued high compensation for chairpersons amidst company troubles is viewed as unreasonable [15].